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Hsp90 is a protein chaperone regulating the stability and activity of many signalling molecules. The requirement of Hsp90 activity in the NF-B pathway has been recently reported by several authors using the Hsp90 ATPase inhibitor Geldanamycin (GA), an anti-tumour drug. Hsp90 inhibition blocks the synthesis and activation of the IKK complex, the major kinases complex responsible for IB phosphorylation on serine 32 and 36, a key step for its degradation and the nuclear translocation of NF-B. However, the effect of GA on other IB kinases, including tyrosine kinases, is unknown. In the present study, we investigated the effect of GA on NF-B activation induced by sodium pervanadate (PV), a tyrosine phosphatase inhibitor triggering c-Src-mediated tyrosine phosphorylation of IB. We reporte for the first time that GA inhibits PV-induced IκBα tyrosine phosphorylation and degradation. Using an in vitro kinase assay, we demonstrated that GA inhibits the activity of c-Src as an IκBα tyrosine kinase, but not its cellular expression. As a result, GA blocked PV-induced NF-κB DNA binding activity on an exogenous κB element and on the endogenous iκbα promoter, thereby inhibiting IκBα transcription. Finally, we demonstrated that, despite NF-κB inhibition, pre-treatment with GA does not potentiate PV-induced apoptosis. We conclude that c-Src requires Hsp90 for its tyrosine kinase activity, and its inhibition by GA blocks c-Src-dependent signalling pathways, such as NF-B activation induced by sodium pervanadate. The effect of GA on PV-induced apoptosis is discussed in the light of recent publications in the literature.













The transcription factor NF-B regulates the expression of numerous genes involved in immune and inflammatory responses, cellular proliferation, differentiation and cell survival [1]. It consists of homo- or heterodimers of a group of five proteins: p50/p105, p52/p100, p65 (RelA), RelB and c-Rel. In unstimulated cells, NF-B is sequestered in the cytoplasm in an inactive form through its association with a member of an inhibitory family of which the most characterized is IB [2]. Pro-inflammatory cytokines (like TNF- or IL-1) induce the classical pathway of NF-B activation, leading to IB phosphorylation on Ser-32 and –36 by the cytoplasmic IB kinase (IKK) complex, which consists of the scaffold protein NEMO/IKKγ and the IKK and IKK kinases [3]. The phosphorylated IκBα is then polyubiquitinated and degraded through the proteasome pathway, making NF-B free to translocate into the nucleus to regulate the expression of many target genes, like ib [4]. Consequently, the newly synthesized IB binds to nuclear NF-B, removes it from its DNA-binding sites and transports it out of the cytosol [3]. An atypical mechanism of NF-B activation, taking place upon cellular stimulation by oxidants like sodium pervanadate, hypoxia/reoxygenation and, in some cell-types, hydrogen peroxide has been described [5-8]. This pathway leads to IB phosphorylation on Tyr42 independently of IKK activation [5-7, 9]. More recently, it has also been described that epidermal growth factor (EGF) and ciliary neurotrophic factor (CNTF) induce tyrosine phosphorylation of IB in lung carcinoma cell lines [10] and in neurons [11], respectively. In HeLa cells, the tyrosine kinase c-Src has been reported to be responsible for tyrosine phosphorylation of IB induced by pervanadate (PV) or hypoxia/reoxygenation [7]. 
The molecular chaperone Hsp90, a heat shock protein of 90 kDa, is one of the most abundant cytosolic proteins in eukaryotic cells. Hsp90 and its co-chaperones control the biogenesis, stability, activity and folding of a number of signalling molecules, including many kinases and transcription factors [12-14]. Hsp90 clients play important roles in the regulation of cell growth, apoptosis and oncogenesis but its mechanism of action is not yet well-known [15]. The main inhibitor of Hsp90 function is geldanamycin (GA), an anti-tumour drug [13, 16, 17]. GA belongs to the benzoquinoid ansamycin antibiotics and was isolated from Streptomyces hygroscopicus [18]. Through its ability to reverse cellular transformation induced by the viral protein v-Src, GA proved to have an anti-tumor activity [19]. Despite the potent anti-cancer activity of GA in cell culture, difficulties in clinical trials were encountered due to its high hepatotoxicity in human tumour models [20]. The GA analogue 17 AAG (17-allylamino-17-demethoxy-geldanamycin) induces less hepatotoxicity, exerts similar anti-tumor activity and could enter Phase I clinical trials [21, 22]. Another derivative, 17 DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin) proved to be more soluble than 17AAG and thus more pharmaceutically practicable [23]. Hsp90 requires ATP binding and hydrolysis to maintain its function and thus the activation of client proteins. This ATPase activity triggers a conformational change in the molecule, switching it between a closed and relaxed state [16, 24-26]. The N-terminal domain of Hsp90 is the binding site for GA and for ATP. GA directly binds to Hsp90, inhibits the ATPase activity and destabilizes the Hsp90-multi-chaperone complexes, resulting in the degradation of client proteins via an ubiquitin-proteasome dependent pathway [13, 16, 17, 27]. Recently, Hsp90 has been found to be a novel regulator of the IKK complex [28-32]. Indeed, Scheidereit and co-workers have shown that Hsp90 is a component of NF-B signalling and is involved in IKK activation [29, 32]. Hsp90 and its co-chaperone Cdc37 have been found to associate stoichiometrically with the IKK complex by binding to the IKK and IKK kinase domains, and GA disrupt this association [28]. When Hsp90 function is inhibited, degradation of IKK subunits seems to be proteasome-dependent but a recent study demonstrated that IKKs can also be selectively degraded by autophagy [13, 16, 29, 30]. On the other hand, a growing list of kinases, including Src family tyrosine kinases, are known to exist as heterocomplexes with Cdc37/Hsp90, allowing their stabilization and activation [12, 13, 33]. Previous works carried out in yeast have revealed that Hsp90 is necessary for the correct folding, maturation, stability and activity of v-Src kinase, the virally encoded counterpart of c-Src [17, 34]. In human cells, this mutated protein is also more susceptible to GA-induced degradation via the ubiquitin-proteasome pathway than c-Src [16, 35]. Despite earlier works having reported that c-Src binds Hsp90 in vitro [36], studies on the effect of Hsp90 inhibitors on c-Src activity are still discrepant. Bijlmakers et al. have reported that Hsp90 is necessary for normal cellular synthesis of c-Src but that GA does not affect total level of c-Src protein [35]. The same result was obtained in neuroblastoma or myoblast cell lines [37, 38]. On the contrary, An et al. reported that prolonged exposure of PC3 cells to GA induce a decrease of c-Src expression [39]. The effect of GA could be thus cell-type dependent. Given that the precise role of Hsp90 on c-Src activity and expression is poorly understood and subject of debates in the literature, we wanted to explore here the effects of GA on the c-Src-dependent NF-B pathway, i.e. those inducing IB tyrosine phosphorylation upon PV stimulation. Using HeLa and Jurkat cell lines, we demonstrate that GA induce a significant reduction of IB tyrosine phosphorylation after PV stimulation. An in vitro kinase assay also revealed that c-Src-mediated IB tyrosine phosphorylation is GA-sensitive, but cellular c-Src expression was not affected by GA. In a second time, we demonstrated that GA blocked PV-induced NF-κB DNA binding activity on an exogenous κB element and on the endogenous iκbα promoter, thereby inhibiting IκBα transcription. Finally, we report that pre-treatment with GA does not potentiate PV-induced apoptosis. We conclude that i) Hsp90 activity is necessary for PV-induced NF-B activation, ii) c-Src requires Hsp90 for its activity, not for its synthesis and iii) the cytotoxicity of PV is not enhanced by GA addition. This result is discussed in the light of recent publications in the literature.   


2. Materials and methods 


2.1. Cell culture and reagents





Monoclonal anti-IB used for western blotting was kindly provided by C. Dagermont (France). Polyclonal anti-IB, IKK and c-Src used for immunoprecipitations and monoclonal anti-IKK, IKK and c-Src used for western blotting were from Santa Cruz Biotechnology (CA, USA). Anti-IB phosphorylated on Ser32 and -36 and anti-phosphotyrosine antibodies were from Cell Signaling Technology (Netherlands). Anti-IKK was from BD Pharmingen (BD Biosciences, CA, USA).

2.3. Western blotting and Electrophoretic Mobility Shift Assay (EMSA)





After treatments, HeLa cells were lyzed for 10 minutes on ice in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, 1mM PMSF and proteases inhibitors (complete, Roche)). Jurkat cells were lysed for 15 minutes on ice in whole cell extraction buffer (25 mM HEPES-KOH, 150 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT, 1 mM Na3VO4, 25 mM -glycerophosphate, 1mM NaF and proteases inhibitors (complete, Roche)). Lysates containing total proteins were incubated with 2 µg/mL of antibodies 2 h at 4°C. Immunocomplex were precipitated using protein G-PLUS-Agarose beads overnight at 4°C. Beads were then washed, boiled for 3 minutes and fractionated in SDS-PAGE.

2.5. In vitro kinase assays 





2.6. Quantitative Real-Time Reverse Transcription-PCR

Total RNA samples were extracted with Tripur isolation reagent (Roche, Mannheim, Germany). 1 g of RNA was submitted to reverse transcription with the M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For quantitative real-time RT-PCR, the obtained cDNA was analyzed, in duplicate, with the SYBR Green Master Mix (Applied Biosystems, Foster city, CA, USA) in the ABI Sequence Detection System. The results were normalized with the 18S transcript. The primers used to analyze the different transcripts were designed with the software Primer ExpressTM (Applied Biosystems): ib, FW 5’- CCAACCAGCCAGAAATTGCT-3’ and RV 5’-TCTCGGAGCTCAGGATCACA-3’; 18S, FW 5’- AACTTTCGATGGTAGTCGCCG-3’ and RV 5’-CCTTGGATGTGGTAGCCGTTT-3’ (Eurogentec).

2.7. Chromatin Immunoprecipitation Assay





2.8. Detection of apoptosis by FACS analysis 







3.1. Geldanamycin inhibits tyrosine phosphorylation of IB 

To study the effects of Geldanamycin (GA, Fig. 1) on IB tyrosine phosphorylation, HeLa and Jurkat cells were pre-treated or not with GA and then stimulated with sodium pervanadate (PV). Because this dose and time of treatment induced very few apoptosis in Jurkat cells (Fig. 2A), we pre-treated cells with GA at a concentration of 0,5 µM during 14h. Nevertheless, we observed that higher concentrations of GA or longer time of 0,5 µM treatment induced apoptosis (Fig. 2A and B). IB was immunoprecipitated and its phosphotyrosine content was detected by western blotting using a specific antibody. As shown in Fig. 3A, IB tyrosine phosphorylation is completely inhibited by GA pre-treatment in Hela cells, whereas this inhibition is more transient in Jurkat. Inhibition of IB tyrosine phosphorylation and degradation was also detected on IB in Western blot, where the apparition of a slower migrating species upon PV stimulation was clearly reduced by GA pre-treatment (Fig. 3A). As control, we also followed IB Ser-32, -36 phosphorylation upon TNF- stimulation with a specific antibody. As expected, GA clearly inhibited TNF--induced Ser-32, -36 IB phosphorylation in both cell lines (Fig. 3B). Altogether, these data suggest that IB phosphorylation on serines and tyrosine relies on Hsp90 activity.

3.2. c-Src-mediated IB tyrosine phosphorlyation is inhibited by Geldanamycin

A recent paper reported that c-Src directly phosphorylates IB on Tyr42 in HeLa cells upon PV stimulation [7]. To further explore the effect of GA on c-Src activity, we carried out an in vitro kinase assay using GST-IB1-55 as substrate. Immunoprecipitated c-Src from PV-treated HeLa cells was able to directly phosphorylate GST-IB on tyrosine (Fig. 4A). The phosphorylated residue is very likely Y42, since there is no other tyrosine residues in the 55 first amino acids of IB [6]. Interestingly, pre-treatment with GA completely inhibited c-Src-mediated IB tyrosine phosphorylation (Fig. 4A). Given that c-Src activity is inhibited in the presence of GA, we analyzed cellular c-Src expression by Western blotting in HeLa cells treated or not with GA. As presented in Fig. 4B, GA treatment has no effect on cellular c-Src expression. We also measured IKK activity in HeLa and Jurkat cells stimulated with TNF- in the presence of GA by immunoprecipitating IKK and carrying out an in vitro kinase assay using the same substrate. GA completely blocked TNF--induced IKK activation in HeLa cells, and nearly completely in Jurkat cells (Fig. 4C). But on the contrary of c-Src and in agreement with others [29], GA induced an important reduction of the expression of IKK and IKK, and a less pronounced reduction of the level of IKK in HeLa and Jurkat cells (Fig. 4D). 

3.3. Geldanamycin inhibits NF-B DNA binding on an exogenous κB site and p65 recruitment on the ib promoter after PV induction

Given that GA inhibited PV-induced IκBα degradation, we next wanted to study the effects of GA on the nuclear phase of the NF-κB pathway, i.e. on NF-B DNA binding activity. HeLa and Jurkat cells were pre-treated or not with GA and then stimulated with PV. NF-B activation induced by TNF-, which has already been reported to be sensitive to Hsp90 inhibition, was used as positive control [29, 41]. Electromobility shift assays (EMSA) performed on nuclear extracts revealed that GA dramatically inhibited NF-B DNA binding activity induced by PV and TNF- in both cell lines (Fig. 5A). To extend these results, we used p65 ChIP assays to determine whether inhibition of NF-B DNA binding observed by EMSA was also confirmed on an endogenous promoter. After chromatin immunoprecipitation with p65 antibody, real time PCR was used to amplify B consensus sequences of the ib promoter. p65 recruitment was observed at 30 min of treatment with PV, and this recruitment is clearly inhibited upon GA pre-treatment (Fig. 5B). The same result were obtained when cells were treated with GA and TNF-.

3.4. Geldanamycin reduces PV-induced IB mRNA synthesis

A quantitative reverse transcription-PCR (qRT-PCR) was used to determine whether IB mRNA synthesis was influenced by GA treatment upon PV stimulation. HeLa cells were treated with PV with or without GA and total RNA were isolated. IB specific primers were used to examine the relative RNA expression. The results were normalized with the 18S transcript. When cells were treated for 30 min with PV alone, a 2-fold stimulation of the IB mRNA synthesis was observed, and is gradually increased at 60 and 120 min of treatment (Fig. 6). Upon GA addition, IB mRNA synthesis was strongly reduced at 60 and 120 min of treatment, bringing it to levels quite comparable to the non-treated signal (Fig. 6). The same data were observed when cells were treated with TNF- plus GA (Fig. 6). 

3.5 Combination of GA and PV treatments has no synergistic effect on apoptosis

























Geldanamycin (GA), an anti-tumour drug, is the main inhibitor of Hsp90, a protein chaperone involved in cytokine-induced NF-B signalling pathways [16, 29]. Pervanadate (PV) induces an atypical NF-B activation pathway, leading to IB phosphorylation on Tyr42 dependent of the tyrosine kinase c-Src [5-7]. Several studies reported an interaction between Hsp90 and c-Src, but the exact role of Hsp90 on c-Src activity and expression is poorly understood [34-36, 39, 43]. In this study, we have investigated the effect of GA on tyrosine phosphorylation dependent NF-B activation, and reporte for the first time that Hsp90 is an essential component for the c-Src-dependent NF-B pathway. First, we have shown that GA inhibits tyrosine phosphorylation and degradation of IB in HeLa and Jurkat cells. As a result, NF-κB nuclear translocation and DNA binding on both an exogenous κB element and on the endogenous iκbα promoter were blocked, thereby inhibiting iκbα mRNA synthesis.  Using an in vitro kinase assay, we also demonstrated for the first time that the activity of c-Src as an IB kinase is completely inhibited by GA in HeLa cells, suggesting that Hsp90 is indeed required for c-Src activity. The same results were obtained in yeast by Xu et al. [34]. Moreover, on the contrary to IKK,  and , we observed that the cellular c-Src expression was not affected by GA treatment. This is in agreement with other works demonstrating that total levels of c-Src are not affected by GA [35, 37], and suggests that the mature protein is stable in the absence of Hsp90 activity. In the same way, the expression of the Src family kinase Lck is unaffected by GA treatment, unless the protein is activated by cellular stimulation [44]. We were unable to detect any c-Src degradation in cells pre-treated by GA and stimulated by PV, even after a long-time activation (data not shown), ruling out the involvement of a general mechanism in the Hsp90-mediated regulation of Src-related tyrosine kinases. In the same way, despite several works reported that some members of Src family kinases, i.e. fyn and v-Src, interact directly with Hsp90 [38, 45], we were unable to reproducibly demonstrate any interaction between Hsp90 and c-Src, mainly due to aspecific binding of Hsp90 to the beads used for immunoprecipitation experiments (data not shown). This observation, in agreement with a recent work [38], reflects the need of more powerful biochemical tools to analyze the interactions between Hsp90 and its partners, which would be highly desirable to avoid artifactual results. 
Since GA was already demonstrated to inhibit the classical NF-B pathway, we thus propose that Hsp90 functions as a key chaperone protein in all NF-B signalling pathways, induced by both serine or tyrosine kinases [29, 46]. On the other hand, since Cdc37 and ELKS have been described to be associated with the IKK complex, we can suggest that these proteins may be associated with c-Src [28, 32, 47].
Interestingly, we also demonstrated in this work that, despite NF-κB inhibition, combination of GA and PV treatments has no significant synergistic effect on Jurkat cells apoptosis. PV-induced apoptosis was reported to rely on the intrinsic mitochondrial pathway and can be blocked by herbimycin A, a tyrosine kinase inhibitor, suggesting that tyrosine kinase activity is crucial in PV-induced cell death [42]. Since GA treatment of activated T cells was reported to deplete important tyrosine kinases, such as Lck [48], it is highly possible that, like herbimycin A, GA reverses PV-induced apoptosis. This result also indicates that NF-κB has no or little role in the protection against cell death induced by PV. It was recently reported that combination of GA and LPS induces macrophage apoptosis [45]. This led us to conclude that GA may have opposite effects on cellular apoptosis depending on the nature of the signalling pathway. 
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Figure 1. Structure of geldanamycin

Figure 2. Effects of various doses and times of GA treatment on Jurkat cell viability 
Jurkat cells were treated with various concentrations of GA for 14h (A) or with 0,5 M of GA during 14h, 24h and 38h (B). Then cells were stained with Annexin V/propidium iodide and subjected to FACS analysis. 

Figure 3. Geldanamycin inhibits tyrosine phosphorylation of IB
A. HeLa and Jurkat cells were pretreated or not with GA (0.5 µM) for 14h and stimulated with PV (200 µM) for the indicated times. Whole cell extracts were prepared and IB was immunoprecipitated. The immunocomplex was then analyzed by Western blotting using phosphotyrosine and IB monoclonal antibodies. B. HeLa and Jurkat cells were pretreated or not with GA (0.5 µM) for 14h and then stimulated with TNF- (200 U/mL) for the indicated times. After treatment, cytoplasmic extracts were prepared and analyzed by Western blotting using a phospho-specific S32-36 anti-IB antibody and a specific anti-IB monoclonal antibody. 

Figure 4. c-Src-mediated IB tyrosine phosphorlyation is inhibited by geldanamycin
A. HeLa cells were pretreated or not with GA (0.5 µM) for 14h and stimulated with PV (200 µM) for the indicated times. After immunoprecipitation of c-Src, an in vitro kinase assay using GST-IB 1-55 was carried out as described in materials and methods. n.s.= no-spécific.Western blotting was then performed using phosphotyrosine and c-Src antibodies (upper panels). Coomassie blue staining of the substrate (cb) is shown as a loading control (lower panel). B. HeLa cells were pretreated or not with GA (0.5 µM) for 14h. After treatment, total extracts were prepared and a western blotting was performed using an anti-c-Src antibody. C. HeLa and Jurkat cells were pretreated or not with GA (0.5 µM) for 14h and then stimulated with TNF- (200 U/mL) for the indicated times. After immunoprecipitation of the IKK complex with an anti-IKK antibody, an in vitro IKK kinase assay was carried out by incubation of the immunoprecipitated proteins with a purified GST-IB 1-55 fusion protein as substrate. A Western blotting was then performed using an antibody specific for Ser32-36 phosphorylated IB and IKK (upper panels). Coomassie blue staining of the substrate (cb) is shown as a loading control (lower panels). D. HeLa and Jurkats cells were pretreated or not with GA (0.5 M) for 14h. The expression levels of IKK,  and  were analyzed by Western blotting.


Figure 5. Geldanamycin inhibits NF-B DNA binding on an exogenous κB site and p65 recruitment on the ib promoter after PV induction
A. HeLa and Jurkat cells were pretreated or not with GA (0.5 µM) for 14h and then stimulated with PV (200 µM) or TNF- (200 U/mL) for the indicated times. After treatment, nuclear extracts were prepared. NF-B DNA binding activity was measured by electromobility shift assay (EMSA) with a probe corresponding to the HIV-1 LTR-B site (upper panels). B. ChIP assays were performed on HeLa cells pre-treated or not with GA and treated with PV or TNF- using p65 antibody for the immunoprecipitation. The immunoprecipitated chromatin was submitted to a quantitative real-time PCR analysis using primers amplifying the promoter region of ib. The fold induction is relative to untreated controls (NT). * significantly different (p value < 0,05). 

Figure 6. Geldanamycin inhibits PV-induced ib mRNA synthesis
Total RNAs were isolated from HeLa cells at various times of treatment with either PV (200 M) or PV+GA (0,5 M) and TNF (200 U/mL) or TNF+GA. IB mRNA expression level was analyzed by quantitative real-time RT-PCR with specific primers. The fold induction is relative to untreated controls (NT). Values are means from three independent experiments.

Figure 7. Combination of GA and PV treatments has not synergistic effect on Jurkat apoptosis
Jurkat cells were treated with GA (0,5 M) for 38h or PV (200 M) for 24h or pretreated with GA for 14h followed by a stimulation with PV for 24h. Fas-L (50 ng/ml, 24h) was used as positive control. Then cells were stained with Annexin V/propidium iodide and subjected to FACS analysis. ns: non significantly different (p value > 0,05).
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